ArticleFrontiers in medicine2026
The high-risk phenotype for gastrointestinal vulnerability in sepsis and 28-day mortality: an integrative study based on clinical association and cross-level biological support.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastrointestinal dysfunction is common in sepsis but remains insufficiently represented in organ-specific risk stratification, partly because bedside gastrointestinal findings are often incompletely captured in structured electronic health record data. We defined gastrointestinal vulnerability phenotype (GIVP) high-risk as a prespecified rule-based electronic health record-operationalized phenotype of early gastrointestinal vulnerability and evaluated its prognostic relevance, incremental risk-stratification value, external prognostic directionality, and cross-level biological plausibility. Methods: This retrospective integrative study used intensive care unit (ICU) admission events with sepsis from the medical information mart for intensive care IV (MIMIC-IV) to construct GIVP high-risk from three prespecified binary domains reflecting early hemodynamic support or hypoperfusion, absence of early enteral nutrition initiation, and early iatrogenic exposure burden. Multivariable logistic regression was used to evaluate the association between GIVP high-risk and fixed-window 28-day mortality. Supportive exposure analyses, sequential organ failure assessment (SOFA)-based stratified analyses, unit-of-analysis sensitivity analyses, Cox sensitivity analysis, incremental prediction analysis, decision curve analysis, and reduced external validation in the eICU collaborative research database (eICU-CRD) were performed. Cross-level biological plausibility was explored using publicly available peripheral blood single-cell transcriptomic data and animal intestinal tissue transcriptomic data. Results: The primary analysis cohort included 28,224 ICU admission events, of which 6,862 resulted in 28-day mortality. In the core model adjusted for age, sex, Charlson Comorbidity Index, infection source, the continuous SOFA score, and renal replacement therapy, GIVP high-risk retained an adjusted association with fixed-window 28-day mortality (OR = 1.216, 95% CI 1.143-1.295; Conclusion: GIVP high-risk is a rule-based electronic health record-operationalized phenotype that retained a prognostic association with 28-day mortality in sepsis after adjustment for clinical context and severity-related variables. Its incremental value was small and context-dependent, with the signal being more evident in higher-severity settings. Reduced external validation supported external prognostic directionality, whereas cross-level transcriptomic analyses supported biological plausibility; neither implied exact external replication nor causal inference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.